Loading…
Employees: 792
Size Shinpoong Pharmaceutical (019170.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $300M, the 462nd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩7,930 on 6 Nov 2026.
Performance Over six months the shares fell 32.2%, against -25.8% for the median peer and -24.5% for the South Korea market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 6.2% over the last twelve months (peer median +1.7%); the operating margin is 1.1% (peer median 5.0%).
Valuation It trades at 1.6× enterprise value to sales against a peer median of 3.1× (5th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +36 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.0 points below its cost of capital (6.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩239B | ₩235B | ₩221B | ₩200B | ₩209B |
| Revenue growth | — | +6% | +10% | -4% | — |
| Gross profit | ₩101B | ₩102B | ₩80.5B | ₩78.6B | ₩77.7B |
| EBITDA | ₩13.8B | ₩25.6B | -₩7.28B | -₩37.1B | -₩21.2B |
| Net income | -₩815M | ₩8.83B | -₩15.4B | -₩57.3B | -₩35.4B |
| Free cash flow | ₩13.6B | ₩13.8B | -₩20.7B | -₩39.7B | -₩31.8B |
| Capital expenditure | ₩4.48B | ₩3.99B | ₩6.09B | ₩15.0B | ₩6.23B |
| Total debt | ₩53.3B | ₩55.9B | ₩54.6B | ₩46.2B | ₩1.93B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 019170.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -28.0% | -11.0% | lowest of 20 |
| 6-month return | -32.2% | -25.8% | 6th lowest of 20 |
| Distance from 52-week high | -50.1% | -45.8% | 6th lowest of 20 |
| Revenue growth (TTM) | +6.2% | +1.7% | 9th highest of 19 |
| Operating margin | 1.1% | 5.0% | 8th lowest of 20 |
| EV / Sales | 1.6× | 3.1× | 5th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 39.9% | 5.6% | most demanding of 13 |
| Growth delivered (Del g) | +3.5% | +1.4% | 6th highest of 13 |
| Hurdle (Req g minus delivered) | +36.4 pp | +7.6 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | -6.0 pp | -5.0 pp | 8th lowest of 19 |
| EV / EBITDA | 28.1× | 12.3× | most expensive of 9 |
| Net debt / EBITDA | -1.4× | 2.0× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shinpoong Pharmaceutical 019170.KS | South Korea | $300M | -32% | +6% | 1% | 1.6× | 39.9% | +3.5% |
| Fuji Pharma 4554.T | Japan | $294M | -19% | +20% | 12% | 1.1× | -6.8% | +8.9% |
| Shanxi C&Y Pharmaceutical 300254.SZ | China | $308M | -44% | -6% | 9% | 3.3× | 10.1% | +0.6% |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 1.0× | -0.1% | -13.7% |
| Zhejiang Zhenyuan Share 000705.SZ | China | $312M | -25% | -33% | -5% | 1.1× | n/a | n/a |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | 66.5× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 1.7× | 5.5% | +62.1% |
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 3.1× | -16.7% | +5.4% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | 2.5× | 5.7% | -0.3% |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | 2.5× | 2.7% | +2.3% |
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | 1.2× | 31.5% | +7.4% |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | 4.8× | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | 3.5× | n/a | n/a |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | 1,229.5× | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |
| Formycon FYB.DE | Germany | $280M | -26% | +18% | -26% | 3.4× | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |